This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E70.2 (Alkaptonuria; same code as tyrosinemia but an entirely different disease, separate file) | OMIM: 203500 | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Alkaptonuria (AKU), Ochronosis, Homogentisic aciduria, homogentisate 1,2-dioxygenase deficiency (HGD deficiency), black urine disease |
| C. Adult onset | Possibility of first presentation in adulthood: high — urine discoloration (black urine) appears from the neonatal period, but complications related to ochronosis of the joints, spine, heart, and other tissues mainly first become clinically problematic in adulthood, after the 30s–40s. It is also common to remain asymptomatic in the neonatal period and childhood and be diagnosed in adulthood. |
| 1. History | 1584: first description of black urine by Scribonius → 1859: Boedeker names it 'Alkaptonurie' → 1902: Archibald Garrod describes it as the founding example of an inborn error of metabolism ('inborn error of metabolism') → 1996: HGD gene cloned → 2025: FDA approval of nitisinone (Harliku®). |
| 2. Causes | Pathogenic variants in the HGD gene (3q13.33) → homogentisate 1,2-dioxygenase (HGD) deficiency → accumulation of homogentisic acid (HGA), an intermediate of the tyrosine degradation pathway → HGA accumulation in blood and tissues and urinary excretion → oxidative polymerization producing a black pigment (benzoquinone acetic acid) → tissue deposition (ochronosis). |
| 3. Genetics | Autosomal recessive. HGD gene (3q13.33), 14 exons, OMIM *607474. More than 180 variants reported. Slovak founder variant (Arg225del). High frequency in some populations, such as in Spain, the Dominican Republic, and Jordan. Rarely reported in Asia. |
| 4. General epidemiology | Worldwide incidence approx. 1:250,000–1:1,000,000. 1:19,000 in some regions of Slovakia due to a founder effect. About 1,000 known patients worldwide. Ultra-rare in Korea. Males and females equally affected. |
| 5. Pathophysiology | HGD deficiency → HGA accumulation in blood → massive urinary HGA excretion (black urine) + HGA deposition in connective tissues (cartilage, tendons, joints) → oxidative polymerization of HGA → formation of high-molecular-weight dark brown pigment (homogentisic acid polymer, benzoquinone acetic acid) → cartilage stiffening, fragility, and progression of osteoarthritis. Pigment deposition = ochronosis. |
| 6. Symptoms | Urine that turns black on exposure to air (immediately darkens when alkalinized). After the 30s–40s: progressive osteoarthritis of the spine, hips, and knees (ochronotic arthropathy), spinal stiffness and pain, heart valve deposition (aortic valve, mitral valve), kidney and prostate stones (HGA stones). Yellowish-brown pigmentation of the auricles, sclerae, and skin. |
| 7. Signs | Bluish-gray to dark brown pigmentation of the auricles and sclerae (directly observable externally). Immediate darkening of urine on alkalinization (diagnostic). Intervertebral disc calcification and narrowing on X-ray (spinal ochronosis). Valve calcification on echocardiography. Increased 24-hour urinary HGA quantification (GC-MS/HPLC). |
| 8. Screening | Not a target of newborn screening (urinary HGA is not included in routine MS/MS screening). Individual diagnosis based on clinical suspicion (black staining of diapers, auricular discoloration). Simple screening with qualitative urine tests (FeCl₃ or darkening reaction of alkalinized urine). Confirmation: 24-hour urinary HGA quantification. |
| 9. Diagnosis | 24-hour urinary HGA quantification (GC-MS or HPLC) — key to confirmation. Urine organic acid analysis (HGA detection). HGD gene NGS molecular testing. Serum HGA (when available). Spine X-ray/MRI (evaluation of ochronotic arthropathy). Echocardiography (valve deposition). Ophthalmological slit-lamp examination (scleral pigment). |
| 10. Treatment | Nitisinone (Harliku®, first FDA approval in 2025): inhibits HPD to block production of the HGA precursor → reduces urinary HGA by 95% or more. Low-tyrosine diet required if blood tyrosine rises. Antioxidants (high-dose ascorbic acid) — used in the past, now adjunctive. Analgesics, physical therapy, joint protection. Orthopedic surgery (joint replacement) for severe arthritis. |
| 11. Prognosis | Alkaptonuria itself is not life-threatening, but progressive disability (joint and spinal complications) markedly reduces quality of life. Early nitisinone treatment prevents HGA accumulation. Ochronosis that has already progressed is not reversed by nitisinone (it has a progression-inhibiting effect). Life expectancy is similar to that of the general population, but the disability burden is large. |
| 12. Prevention | Primary: genetic counseling, family genetic testing, prenatal diagnosis. Secondary: early urinary HGA testing when clinically suspected, early initiation of nitisinone treatment (prevention of progressive ochronosis). Tertiary: joint-protective lifestyle, regular echocardiography and spinal imaging, pain management, kidney stone monitoring, dietary tyrosine control. |
| 13. References | Garrod AE. About alkaptonuria. Lancet. 1902. and 9 other papers |
Alkaptonuria is one of the oldest recorded hereditary metabolic diseases in human history. The first record of black urine was made in 1584 by the German physician Scribonius, followed by intermittent case reports over several centuries. In 1859, the German chemist Carl Heinrich Dietrich Boedeker isolated the substance that turns urine black on exposure to air and named it Alkapton, from a Greek-derived term meaning 'alkali-greedy,' and named the condition of excreting this substance "Alkaptonurie."
The most important place of alkaptonuria in medical history derives from the paper published in Lancet in 1902 by the British physician Archibald E. Garrod (1857–1936). Garrod explained several rare metabolic abnormalities, including alkaptonuria, cystinuria, pentosuria, and albinism, by combining analysis of patterns of occurrence within families with Mendel's laws of inheritance, and named them "inborn errors of metabolism". This was the first proposal of the concept that enzyme deficiency at a specific metabolic step is transmitted genetically, and it became the starting point of modern biochemical genetics. His 1909 book Inborn Errors of Metabolism remains a classic in the field.
In 1958, La Du et al. demonstrated that homogentisate 1,2-dioxygenase (HGD) activity is absent in the livers of alkaptonuria patients, directly confirming that homogentisic acid (HGA) accumulates because it cannot be degraded. This clearly established the biochemical cause of alkaptonuria. The HGD gene was cloned in 1996 and located on the long arm of chromosome 3 (3q13.33), and since then more than 180 pathogenic HGD variants have been reported worldwide.
A notable event in the history of treatment was the discovery that nitisinone, a treatment for tyrosinemia type 1, dramatically reduces urinary HGA in alkaptonuria. Because nitisinone inhibits the enzyme (HPD) at the step upstream of HGA production, HGA production itself is blocked. The HGA-lowering effect of nitisinone (95% or greater reduction in urinary HGA) was demonstrated through the UK alkaptonuria registry study (DevelopAKUre project) and a series of clinical trials, and in June 2025 the US FDA approved nitisinone (brand name Harliku®) as the first disease progression-inhibiting treatment for alkaptonuria. This was a historic event in which evidence-based treatment for the disease was established for the first time more than 120 years after Garrod's 1902 discovery.
In Korea, alkaptonuria is reported very rarely, and in most cases it is diagnosed on the occasion of adult low back pain or arthritis, or incidentally discovered black urine. The ICD-10 code used is E70.2, which is the same code as tyrosinemia, so particular care is needed in clinical records.
Alkaptonuria is an autosomal recessive metabolic disease caused by an inherited deficiency of homogentisate 1,2-dioxygenase (HGD), an intermediate enzyme of the tyrosine degradation pathway. The HGD gene is located on the long arm of chromosome 3 (3q13.33). The HGD enzyme catalyzes the oxidative cleavage of homogentisic acid (HGA) to maleylacetoacetate in the tyrosine degradation pathway. This process requires molecular oxygen and ferrous iron (Fe²⁺).
In HGD deficiency, HGA accumulates excessively in the blood and tissues. HGA, of which only trace amounts are normally excreted in the urine, is excreted in large amounts of 1–8 g per day in alkaptonuria. On contact with air, HGA is oxidized to form a black-brown polymer, benzoquinone acetic acid, and related polymeric pigments. This is why urine turns black on standing.
The more important pathology is the deposition of HGA and its oxidized polymers in connective tissue, particularly cartilage, tendons, ligaments, and bone. This deposition process is called ochronosis, and to distinguish it from endogenous ochronosis it is differentiated from exogenous ochronosis (e.g., that caused by topical phenolic compounds). Ochronosis in alkaptonuria is endogenous (endogenous ochronosis). HGA polymers bind covalently to cartilage collagen fibers, hardening and weakening the cartilage, and this is the pathological basis of progressive osteoarthritis.
HGA can also deposit in the kidneys, prostate, salivary glands, and heart valves, causing renal and prostatic stones and valvular dysfunction. Studies have reported that HGA may also affect mitochondrial function. Unlike tyrosinemia (FAH deficiency), alkaptonuria does not produce the toxic metabolites FAA, MAA, and succinylacetone, so there is no direct hepatic or renal toxicity or porphyria-like crisis. This is the fundamental pathological difference between the two diseases.
The HGD enzyme is expressed mainly in the liver, but also in the kidney and small intestine. When tyrosine degradation is blocked at this step owing to deficiency of these enzymes, metabolites of the steps before HGA (e.g., 4-HPP) remain within nearly normal ranges. Blood tyrosine is normal or only mildly elevated, so alkaptonuria is not detected by tyrosine measurement in newborn screening.
Alkaptonuria follows autosomal recessive inheritance and occurs only when both alleles of the HGD gene (OMIM *607474) carry pathogenic variants. The HGD gene is located on the long arm of chromosome 3 at q13.33 and has 14 exons and a genomic length of 54 kb. The mature protein consists of 445 amino acids and functions as a homohexamer (two trimeric units), forming a ring structure.
The international alkaptonuria variant database (HGD database, led by the University of Jaén, Spain) listed more than 180 HGD variants as of 2024. By variant type, missense variants are the most common (about 60%), followed by splicing variants, small deletions/insertions, and nonsense variants. Concentrations of variant frequency due to founder effects are observed in certain populations. In the Slovak population, p.Arg225del (c.674_676delTCA) is a founder variant, and the incidence of alkaptonuria in this region is high at about 1:19,000. Respective founder variants have also been identified in Spain (Canary Islands), the Dominican Republic, and Jordan.
HGD variants are reported relatively rarely in Asian patients, but as case reports from Asia, including Korea, have recently increased, Asian-specific variants are gradually being identified. p.Val300Gly has been reported in Japanese patients, and various missense variants have also been reported in Chinese patients. Reports of HGD variants in Korea are extremely rare, and systematic molecular genetic data are lacking.
The genotype–phenotype correlation is weak. That is, a specific HGD variant does not fully predict disease severity (e.g., the rate of progression of ochronosis or the timing of complications). This is presumed to reflect the combined effects of environmental factors (diet, oxidative stress), age, and other modifier genes. Both homozygotes and compound heterozygotes can show similar clinical phenotypes.
In genetic counseling, the recurrence risk for children of carrier parents is 25% (Mendelian inheritance). When there is a family history, prenatal genetic diagnosis (chorionic villus sampling or amniocentesis) is possible. However, because alkaptonuria is a late-onset disease that is asymptomatic in childhood and adolescence with complications arising in adulthood, genetic counseling must consider both the ethical aspects of prenatal diagnosis and the availability of treatment.
Alkaptonuria is a rare disease, with a worldwide incidence estimated at about 1:250,000–1:1,000,000. However, incidence varies greatly by region. In certain areas of Slovakia (e.g., Liptovská Lúžna), an incidence of about 1:19,000 has been reported owing to a founder effect, making it one of the regions with the highest confirmed incidence in the world. Relatively high frequencies have also been reported in Spain (Canary Islands), the Dominican Republic, Jordan, and North Africa.
The number of known alkaptonuria patients worldwide is estimated at around 1,000, and several hundred patients are enrolled in the European alkaptonuria patient registry study (DevelopAKUre). The sex distribution is equal, but some studies have reported that osteoarthritis complications tend to appear earlier and be more severe in men. This is presumed to be due to differences in physical activity and joint loading in men.
In Korea, alkaptonuria is an ultra-rare disease known only from literature reports. Most cases are diagnosed in adults, prompted by incidentally discovered black urine, spinal osteoarthritis, or black-brown cartilage found during arthroscopic surgery. Because it is not included in newborn screening, diagnosis in childhood is rare, and there are cases diagnosed when parents notice urine discoloration (discoloration of diapers or urine).
Alkaptonuria is classified as E70.2 in ICD-10, the same code as tyrosinemia. The two are separate diseases involving different enzymes of the tyrosine degradation pathway, and their clinical features are completely different, so care is needed when using the code. Special Copayment Reduction V117 applies, and it is registered as a rare disease.
The pathogenesis of alkaptonuria is understood as a sequential process of HGA accumulation due to HGD enzyme deficiency, its oxidative polymerization, and pigment deposition in tissues.
In the normal tyrosine degradation pathway, tyrosine is converted by tyrosine aminotransferase (TAT) to 4-hydroxyphenylpyruvic acid (4-HPP), converted by HPD to homogentisic acid (HGA), and then oxidatively ring-cleaved by HGD to maleylacetoacetate. When HGD is deficient, the reaction is blocked at this step and HGA accumulates excessively in the blood and tissues.
Blood HGA is excreted by the kidneys mainly through glomerular filtration, resulting in massive homogentisic aciduria (normal <20 mg/day vs. AKU >1,000–8,000 mg/day). Urinary HGA is rapidly oxidized and polymerized at alkaline pH or on exposure to air by a polyphenol oxidase-like reaction, forming a black-brown pigment. This appears as the black discoloration of urine left standing.
In tissues, HGA travels through the bloodstream to connective tissue and forms covalent bonds with collagen fibers. This binding is promoted by oxidation, and the HGA polymer benzoquinone acetic acid (BQA) accumulates irreversibly within collagen fibers. This is the substance of the black-brown pigmentation (ochronosis) observed in articular cartilage, intervertebral discs, tendons, ligaments, sclera, auricular cartilage, heart valves, and vessel walls. HGA polymers increase cross-linking between collagen fibers, hardening and weakening the cartilage, which ultimately results in cartilage fragmentation, joint space narrowing, and progression of osteoarthritis.
Ochronotic arthropathy progresses faster particularly in the spinal intervertebral discs, hips, and knees, which bear heavy weight loads. HGA deposition in the heart valves (mainly the aortic and mitral valves) can lead to valvular sclerosis and dysfunction. In the kidneys and prostate, HGA crystals can form renal and prostatic stones.
Regarding mitochondrial function, there is experimental evidence that HGA interferes with the electron transport chain, and it has been hypothesized that this may contribute to some of the systemic symptoms of alkaptonuria.
The clinical symptoms of alkaptonuria appear in characteristic stages according to age.
Neonatal and infancy period — black urine: Brown-to-black stains found on diapers or in urine are the first clue. If noticed in the neonatal period, diagnosis can be made relatively early. The urine itself is yellow when fresh, but turns black rapidly on standing or alkalinization.
Childhood and adolescence — asymptomatic stage: Most children have no clinical symptoms other than black urine. In some, blue-gray pigmentation of the auricle (pinna) may begin to appear gradually.
Adulthood (mainly 30s–50s) — musculoskeletal symptoms: The most serious complications of alkaptonuria appear during this period. Spinal ochronotic arthropathy: progressive stiffness and pain of the lumbar and thoracic spine, and disc space narrowing and calcification appear with X-ray findings resembling ankylosing spondylitis. Peripheral joint osteoarthritis: mainly involves the hips, knees, and shoulders. Black-brown discolored cartilage observed during arthroscopy or surgery may be a diagnostic clue.
Cardiovascular system: valvular sclerosis and valvular dysfunction (stenosis or regurgitation) due to ochronosis of the aortic and mitral valves. Calcification of the aorta and coronary arteries may occur early.
Urinary system: increased risk of renal and prostatic stones.
External pigmentation: blue-gray to black-brown triangular pigmentation of the sclera (Osler's sign) and blue-gray discoloration of the auricular cartilage are important external signs that noninvasively suggest ochronosis.
The clinical signs of alkaptonuria that can be objectively confirmed are as follows.
Auricular (pinna) pigmentation: blue-gray to black-brown discoloration of the auricular cartilage is the most characteristic external sign of adult alkaptonuria. The cartilage pigment is seen through the skin, and recognizing the typical color is very useful for diagnosis.
Scleral pigmentation: on slit-lamp or gross examination, blue-gray to black-brown triangular pigmentation of the sclera near the corneal limbus is observed (Osler's sign). It is particularly evident in the lateral sclera of both eyes.
Blackening of urine (on alkalinization): when fresh urine is alkalinized with sodium hydroxide (NaOH) solution, it immediately turns black. Urine left standing also turns black within minutes to hours. This simple test provides an immediate diagnostic clue in suspected patients.
Spinal X-ray abnormalities: spinal radiographs show disc calcification, disc space narrowing, and osteophyte formation along the entire lumbar to thoracic spine. It resembles ankylosing spondylitis, but disc calcification is more characteristic of alkaptonuria.
Echocardiographic abnormalities: calcification of the aortic and mitral valves, valve thickening, and valvular dysfunction (stenosis or regurgitation) may be observed.
Elevated 24-hour urine HGA: quantitative analysis (GC-MS or HPLC) shows excretion of 1–8 g of HGA per day (normal <20 mg/day). This is the key indicator for biochemical confirmation.
Elevated serum HGA: serum HGA is measured at institutions capable of specialized testing and used for confirmation.
Alkaptonuria is currently not included in standard newborn screening (MS/MS) in most countries, including Korea. This is because blood tyrosine is normal or only mildly elevated and is not detected by tyrosine-based screening. In addition, HGA is not included in routine newborn screening MS/MS panels.
Qualitative urine testing based on clinical suspicion: the simplest screening method is qualitative urine testing. ① Adding a few drops of 10% sodium hydroxide (NaOH) to fresh urine turns it black immediately if HGA is present. ② Treating urine with an oxidizing agent (FeCl₃ reagent or silver nitrate reagent) produces a black-brown reaction. ③ Leaving urine exposed to air for several hours causes it to turn black gradually. These tests are useful screening tools that can be performed immediately on site in patients referred because of brown stains on diapers or black urine in adults.
Urine organic acid analysis (GC-MS): if HGA is included in the urine organic acid panel, abnormal excretion may be identified. When performing urine organic acid testing to screen for metabolic diseases, it is important to include alkaptonuria in the differential diagnosis.
Imaging clues: in adults, if disc calcification is seen on spinal X-ray or black-brown discoloration of cartilage is observed during arthroscopic surgery, alkaptonuria should be suspected and urine HGA testing requested.
Family screening: qualitative urine testing and HGD gene testing are recommended for siblings of patients with alkaptonuria. If a known HGD variant exists in the family, targeted variant analysis is possible.
Alkaptonuria is confirmed by quantitative urine HGA analysis and HGD gene testing.
24-hour urine HGA quantification (GC-MS or HPLC): the key test for confirming alkaptonuria. A 24-hour urine sample is collected and HGA is quantified by GC-MS or HPLC. In alkaptonuria, HGA excretion is 1,000–8,000 mg per day, tens to hundreds of times higher than normal (less than 20 mg/day). It is important to acidify the urine during collection (adding hydrochloric acid or ascorbic acid) to prevent oxidation of HGA.
Urine organic acid analysis (GC-MS): an HGA peak is detected, and related oxidized derivatives are also identified. Even when clinical symptoms are atypical, an incidental finding of elevated HGA on urine organic acid analysis may lead to the diagnosis.
Serum HGA measurement: serum HGA quantification is available at some specialized laboratories. It serves as a confirmatory tool that complements urine testing.
HGD gene molecular genetic testing: after clinical and biochemical diagnosis, NGS-based direct sequencing of the HGD gene and exon deletion/duplication analysis are performed for molecular confirmation, family screening, and prenatal diagnosis.
Musculoskeletal imaging: spinal X-ray (disc calcification, narrowing), spinal MRI (cartilage changes, abnormal disc signal). Hip and knee X-rays (cartilage loss, joint space narrowing). These imaging findings are essential for assessing the extent of complications after diagnosis.
Echocardiography: performed regularly to assess heart valve lesions (valve calcification, reduced valve area, degree of regurgitation).
Ophthalmic examination (slit lamp): confirms the extent and location of scleral pigmentation. In the early stage, it may be observable only with a slit lamp.
Before FDA approval in June 2025, there was no approved therapy that slowed disease progression in alkaptonuria, and treatment was conservative, focused on symptom relief and management of complications. The approval of nitisinone (Harliku®) in 2025 opened a new era of treatment.
Nitisinone (Harliku®, FDA approval June 2025): competitively inhibits HPD (4-hydroxyphenylpyruvate dioxygenase), the enzyme of the step before HGA formation in the tyrosine degradation pathway. HPD inhibition → blocks HGA formation itself → reduces urine HGA by more than 95%. Clinical trials confirmed the reduction in HGA, but reversal of already advanced ochronosis is difficult, and the main benefit is progression arrest. Dose: adults 2 mg/day (may be adjusted based on body weight). Adverse effects: elevated blood tyrosine (a secondary consequence of HPD inhibition) → risk of corneal crystal deposition and corneal damage, so a low-tyrosine diet and regular ophthalmic examinations are needed. In Korea, its use as a rare disease treatment is under discussion.
Vitamin C (ascorbic acid, high dose): an antioxidant effect inhibiting the oxidative polymerization of HGA was proposed, and it was widely used in the past. However, clinical trials did not demonstrate a significant effect on inhibiting the progression of ochronosis, so it currently plays only an adjunctive role.
Low-tyrosine, low-phenylalanine diet: reducing intake of tyrosine, the precursor of HGA, could theoretically reduce HGA production. During nitisinone treatment, dietary restriction is needed to suppress the rise in blood tyrosine.
Management of musculoskeletal complications: physical therapy, low-impact aerobic exercise, joint-protective devices. Pain control (NSAIDs, acetaminophen, intra-articular corticosteroid injections if needed). Joint replacement for severe osteoarthritis (total hip and knee replacement). Surgery considered for spinal lesions (in severe compression fractures or spinal stenosis).
Heart valve lesions: valvuloplasty or valve replacement when there is severe valvular dysfunction.
Kidney stones: increased fluid intake; surgical removal of urinary stones if needed.
Alkaptonuria itself is not a life-threatening disease, and patients' life expectancy is similar to that of the general population. However, the key problem is that chronic pain, reduced motor function, and social and occupational limitations due to progressive ochronotic arthropathy markedly lower quality of life.
The clinical course varies greatly between individuals, but overall, ochronosis-related complications begin to progress from the late 30s to 40s, and after the 50s most patients develop significant spinal and joint dysfunction. The correlation between annual HGA accumulation and clinical severity observed in a UK prospective cohort study (NAC trial) suggests that reducing HGA will inhibit the progression of ochronosis in the long term.
Whether early HGA-lowering treatment with nitisinone can prevent the progression of ochronosis is currently a major research question. In clinical trials, urine HGA decreased by more than 95%, but ochronosis that had already progressed (pigment deposition in cartilage) was confirmed not to reverse. Therefore, starting treatment as early as possible is advantageous for improving prognosis.
When heart valve lesions progress to a severe stage, surgical treatment is needed, and this complication can affect mortality. Renal and prostatic stones tend to recur and require ongoing management.
Psychologically, chronic pain and progressive functional decline are associated with depression and reduced quality of life, and the role of patient support groups (e.g., the AKU Society) is important.
The key to preventing alkaptonuria is preventing complications and slowing progression through early diagnosis.
Primary prevention: genetic counseling and HGD carrier testing for family members of confirmed patients. Early identification of affected fetuses in subsequent pregnancies through prenatal diagnosis (chorionic villus sampling or amniocentesis). However, because alkaptonuria has a long asymptomatic period from the neonatal period through childhood and is becoming a treatable disease in adulthood, social and ethical considerations of prenatal diagnosis must also be addressed.
Secondary prevention (early diagnosis): it is important to recognize clinical clues of black urine, such as brown stains on diapers and urine discoloration, and to perform urine HGA testing early. Evidence is accumulating that starting nitisinone treatment as early as possible after early diagnosis to prevent HGA accumulation can inhibit the development and progression of ochronosis. In adults, if ochronosis-related findings such as spinal disc calcification or black-brown cartilage during arthroscopic surgery are found, urine HGA should be tested without delay.
Tertiary prevention (minimizing complications): after confirmation, regular joint and spine imaging follow-up (at least once a year), echocardiography (every 2–3 years), renal ultrasound (monitoring for kidney stones). Low-impact exercise such as swimming and cycling recommended for joint protection; avoidance of high-impact exercise. Blood tyrosine monitoring during nitisinone treatment (target <500 μmol/L), regular ophthalmic slit-lamp examination (monitoring for corneal crystals). Pain management and physical therapy, with orthopedic surgery planned if needed. Patient education and connection to support groups.